Probiotics, Prebiotics, Synbiotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives
- PMID: 32472285
- DOI: 10.1007/s13679-020-00379-w
Probiotics, Prebiotics, Synbiotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives
Abstract
Purpose of review: In this review, we summarize current evidence on gut microbiome and obesity; we discuss the role of probiotics, prebiotics, synbiotics, and postbiotics in obesity prevention and management; and we highlight and analyze main limitations, challenges, and controversies of their use.
Recent findings: Overall, the majority of animal studies and meta-analyses of human studies examining the use of probiotics and synbiotics in obesity has shown their beneficial effects on weight reduction and other metabolic parameters via their involvement in gut microbiota modulation. Bifidobacterium and Lactobacillus strains are still the most widely used probiotics in functional foods and dietary supplements, but next generation probiotics, such as Faecalibacterium prausnitzii, Akkermansia muciniphila, or Clostridia strains, have demonstrated promising results. On the contrary, meta-analyses of human studies on the use of prebiotics in obesity have yielded contradictory results. In animal studies, postbiotics, mainly short-chain fatty acids, may increase energy expenditure through induction of thermogenesis in brown adipose tissue as well as browning of the white adipose tissue. The main limitations of studies on biotics in obesity include the paucity of human studies; heterogeneity among the studied subgroups regarding age, gender, and lifestyle; and use of different agents with potential therapeutic effects in different formulations, doses, ratio and different pharmacodynamics/pharmacokinetics. In terms of safety, the supplementation with prebiotics, probiotics, and synbiotics has not been associated with serious adverse effects among immune-competent individuals, with the exception of the use of probiotics and synbiotics in immunocompromised patients. Further large-scale Randomized Controlled Trials (RCTs) in humans are required to evaluate the beneficial properties of probiotics, prebiotics, synbiotics, and postbiotics; their ideal dose; the duration of supplementation; and the durability of their beneficial effects as well as their safety profile in the prevention and management of obesity.
Keywords: Diet; Gut; Intestine; Metabolic syndrome; Microbiome; Microbiota; Obesity; Postbiotics; Prebiotics; Probiotics; Sybiotics.
Similar articles
-
Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era.Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7588-7605. doi: 10.26355/eurrev_201811_16301. Eur Rev Med Pharmacol Sci. 2018. PMID: 30468509
-
GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN MANAGEMENT OF OBESITY AND PREDIABETES: REVIEW OF RANDOMIZED CONTROLLED TRIALS.Endocr Pract. 2016 Oct;22(10):1224-1234. doi: 10.4158/EP151157.RA. Epub 2016 Jul 13. Endocr Pract. 2016. PMID: 27409822 Review.
-
Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review.Nutrients. 2021 Sep 15;13(9):3211. doi: 10.3390/nu13093211. Nutrients. 2021. PMID: 34579087 Free PMC article. Review.
-
Prebiotics, probiotics, synbiotics and postbiotics to adolescents in metabolic syndrome.Clin Nutr. 2024 Jun;43(6):1433-1446. doi: 10.1016/j.clnu.2024.04.032. Epub 2024 Apr 22. Clin Nutr. 2024. PMID: 38704983 Review.
-
The microbiome: An actor or stage for the beneficial action of probiotics, prebiotics, synbiotics, and postbiotics?Cell Host Microbe. 2025 Jun 11;33(6):777-789. doi: 10.1016/j.chom.2025.04.017. Cell Host Microbe. 2025. PMID: 40505618 Review.
Cited by
-
NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options.Metabolites. 2024 Jun 28;14(7):366. doi: 10.3390/metabo14070366. Metabolites. 2024. PMID: 39057689 Free PMC article. Review.
-
Vaginal microbiota: Potential targets for vulvovaginal candidiasis infection.Heliyon. 2024 Mar 2;10(5):e27239. doi: 10.1016/j.heliyon.2024.e27239. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463778 Free PMC article. Review.
-
Mycobiome and Cancer: What Is the Evidence?Cancers (Basel). 2021 Jun 24;13(13):3149. doi: 10.3390/cancers13133149. Cancers (Basel). 2021. PMID: 34202433 Free PMC article. Review.
-
Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try.Clin Mol Hepatol. 2021 Jan;27(1):83-86. doi: 10.3350/cmh.2020.0298. Epub 2020 Dec 3. Clin Mol Hepatol. 2021. PMID: 33317240 Free PMC article. No abstract available.
-
Synbiotic Effects of Lacticaseibacillus paracasei K56 and Prebiotics on the Intestinal Microecology of Children with Obesity.Probiotics Antimicrob Proteins. 2024 Nov 6. doi: 10.1007/s12602-024-10395-0. Online ahead of print. Probiotics Antimicrob Proteins. 2024. PMID: 39503979
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials